Northwell Health is New York’s Most Awarded Health System by U.S. News

Northwell’s North Shore University Hospital was ranked No. 1 in the state and in the top 20 hospitals in the nation in the 2023-24 Best Hospital rankings by U.S. News & World Report. Two other Northwell hospitals also placed in the top 10 in state rankings, and dozens of programs across the health system were also ranked incredibly well.

Overall, eight Northwell hospitals were ranked among the best in New York. North Shore University Hospital tied for being named the best hospital in the state. Lenox Hill Hospital in Manhattan was ranked No. 5, and Long Island Jewish Medical Center tied for No. 6.

U.S. News also ranked hospitals’ specialty services nationally, and three Northwell programs were ranked in the top 10: Lenox Hill was ranked No. 10 for heart and vascular surgery, and North Shore was ranked No. 10 in both orthopedics as well as pulmonary and lung surgery. Systemwide, 31 Northwell specialty programs received rankings.

“Every day, I see the amazing care our team delivers to our patients and that is reflected in these impressive rankings,” said Michael Dowling, president and CEO of Northwell Health.   “We are proud to see Northwell recognized as New York State’s most-awarded health system.  These last few years have been challenging, but we have never stopped working to raise the health of the patients and communities we serve.”

Eight of the hospitals in the Northwell health system were ranked among the best in the state. They are: North Shore University Hospital (1st, tied); Lenox Hill Hospital (5th); Long Island Jewish Medical Center (6th, tied);  Huntington Hospital (11th); South Shore University Hospital (12th); Staten Island University Hospital (13th, tied); Northern Westchester Hospital (24th, tied); and Plainview Hospital (29th, tied).

Lenox Hill earned top 50 status in 10 specialties: Heart and vascular (10th); Obstetrics and gynecology (16th); Geriatrics (18th); Pulmonology and lung surgery (22nd); Ear, nose and throat (30th); Orthopedics (32nd); Diabetes and endocrinology (36th); Urology (38th); Neurology and neurosurgery (40th); and Cancer (43rd).

North Shore earned top 50 status in nine specialties: Orthopedics (10th); Pulmonary and lung surgery (10th); Heart and vascular (12th); Diabetes and endocrinology (12th); Gastroenterology and GI surgery (12th); Geriatrics (16th); Urology (17th); Neurology and neurosurgery (19th); and Cancer (26th).

LIJ also earned top 50 status in nine specialties: Obstetrics and gynecology (11th); Neurology and neurosurgery (15th); Diabetes and endocrinology (19th); Pulmonary and lung surgery (28th); Geriatrics (29th); Ear, nose and throat (29th); Orthopedics (34th); Gastroenterology and GI surgery (40th); and Urology (47th).

Additionally, Huntington Hospital was ranked 33rd for geriatrics and 38th for pulmonary and lung surgery, and Plainview Hospital was ranked 46th for diabetes and endocrinology care.

The 2023-24 rankings are an improvement for Northwell. The health system has more hospitals ranked as the top in the state, and has more specialties ranked nationally as well.

“North Shore University Hospital is always pushing forward, and our reputation for advancing healthcare is only strengthened by being recognized as the No. 1 hospital in New York,” said Jon Sendach, executive director of North Shore. “This prestigious ranking recognizes the talent and sophistication of the thousands of healthcare professionals who practice here, and their enduring commitment to excellence.”

U.S. News released a separate ranking one children’s hospitals in June. In that ranking, Northwell’s Cohen Children’s Medical Center was ranked the No. 1 children’s hospital on Long Island and the second-best in the state.

This marks the 34th edition of U.S. News’ Best Hospitals rankings. Its methodologies in most areas of care are based largely on objective measures such as patient outcomes and discharge-to-home rates, volume and quality of nursing, among other care-related indicators. U.S. News evaluated nearly 4,500 medical centers nationwide in 15 specialties, and more than 20 procedures and conditions to compile its 2023-24 rankings. Only 164 hospitals in the nation were ranked in at least one specialty.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version